Apigenin, a natural plant compound found in chamomile and parsley, significantly reduced fatty liver disease in mice by changing gut bacteria composition and lowering harmful homocysteine levels, according to Gram Research analysis. The compound decreased liver fat accumulation, improved liver function markers, and reduced inflammation and oxidative stress. While these findings are promising, human studies are needed before apigenin can be recommended as a treatment for fatty liver disease.
Researchers discovered that apigenin, a natural compound found in plants like chamomile and parsley, may help reverse fatty liver disease by changing the bacteria in your gut. In a study using mice, apigenin reduced fat buildup in the liver, improved liver function, and reduced inflammation and damage from harmful molecules. The compound worked by shifting the balance of gut bacteria and lowering levels of a harmful substance called homocysteine. These findings suggest apigenin could become a natural treatment option for metabolic-associated fatty liver disease, a condition affecting millions of people worldwide.
Key Statistics
A 2026 research article published in Phytomedicine found that apigenin treatment markedly reduced hepatic triglyceride accumulation and improved liver function markers in mice with methionine-choline deficient diet-induced fatty liver disease.
According to research reviewed by Gram, apigenin remodeled gut microbiota by increasing beneficial Lactobacillus abundance while decreasing Akkermansia, and lowered homocysteine levels—a key metabolite linked to oxidative stress and fatty liver disease.
The study demonstrated that apigenin decreased saturated and polyunsaturated fatty acids in the liver while increasing monounsaturated fatty acids, shifting the liver’s fat composition toward a healthier profile in mice with fatty liver disease.
The Quick Take
- What they studied: Whether apigenin, a natural plant compound, could treat fatty liver disease and how it works in the body
- Who participated: Laboratory mice fed a special diet designed to cause fatty liver disease, compared to mice receiving apigenin treatment
- Key finding: Apigenin significantly reduced fat accumulation in the liver, improved liver function markers, and decreased inflammation and oxidative stress in mice with fatty liver disease
- What it means for you: This research suggests apigenin could potentially become a natural treatment for fatty liver disease, though human studies are needed before it can be recommended as a therapy. People with fatty liver disease should discuss this research with their doctor but shouldn’t self-treat without medical guidance.
The Research Details
Scientists created a mouse model of fatty liver disease by feeding them a special diet lacking two important nutrients: methionine and choline. This diet causes the same type of liver damage seen in humans with metabolic-associated fatty liver disease. Some mice received apigenin treatment while others didn’t, allowing researchers to compare the effects.
The researchers used advanced laboratory techniques to measure multiple aspects of liver health, including fat content, liver function markers, inflammation levels, and oxidative stress (damage from harmful molecules). They also analyzed the composition of gut bacteria and measured metabolites—chemical substances produced by the body and gut bacteria.
This comprehensive approach allowed them to not only see whether apigenin worked, but also understand the mechanisms—the biological pathways—through which it produced its beneficial effects.
This research approach is important because fatty liver disease is complex and involves multiple body systems working together. By examining the gut microbiota (the community of bacteria in your digestive system) and how it connects to liver function, researchers can identify new treatment targets. Understanding the mechanism helps explain why apigenin works and could lead to better treatments for humans.
This study used a well-established animal model of fatty liver disease and employed multiple advanced analytical techniques to measure outcomes. The use of lipidomic profiling (detailed analysis of fats) and microbiota analysis provides comprehensive data. However, because this is an animal study, results may not directly translate to humans. The study was published in a peer-reviewed journal, indicating it underwent expert evaluation. The specific sample size for mice wasn’t provided in the abstract, which is a minor limitation for assessing statistical power.
What the Results Show
Apigenin treatment markedly reduced fat buildup in the livers of mice with fatty liver disease. The compound decreased the accumulation of triglycerides (a type of fat) in liver cells, which is the hallmark of fatty liver disease. Additionally, apigenin improved liver function markers, suggesting the organ was working better overall.
The treatment also reduced two major problems associated with fatty liver disease: inflammation (swelling and immune activation) and oxidative stress (damage from harmful molecules called free radicals). These improvements are significant because inflammation and oxidative stress drive the progression of fatty liver disease and can lead to more serious liver damage.
Detailed analysis of liver fats showed that apigenin changed the composition of fats in the liver. Specifically, it decreased saturated fats and certain polyunsaturated fats while increasing monounsaturated fats—a shift toward a healthier fat profile. This suggests apigenin doesn’t just reduce total fat, but improves the type of fat stored in the liver.
The research identified how apigenin produces its benefits: by changing the composition of gut bacteria. Apigenin increased the abundance of Lactobacillus (considered beneficial bacteria) while decreasing Akkermansia (which may contribute to liver disease). This microbial remodeling is important because gut bacteria influence liver health through multiple pathways.
The study identified homocysteine as a key link between gut bacteria changes and liver health. Homocysteine is an amino acid that, at high levels, can cause oxidative stress and damage. Apigenin lowered homocysteine levels, which appears to be one mechanism through which it protects the liver. This finding connects the gut microbiota to liver lipid metabolism, showing how changes in bacteria can influence how the liver processes fats.
Apigenin has been studied for various health benefits in previous research, including antioxidant and anti-inflammatory effects. This study builds on that foundation by demonstrating a specific application—treating fatty liver disease—and by identifying the gut microbiota as a key mechanism. The focus on the gut-liver axis (the connection between gut bacteria and liver function) represents an emerging area of research that explains how many natural compounds may benefit liver health. This research aligns with growing evidence that gut bacteria play a crucial role in metabolic diseases.
This study was conducted in mice, not humans, so results may not directly apply to people. Mouse models can differ significantly from human biology and disease progression. The study doesn’t specify the exact number of mice used, making it difficult to assess statistical power. Additionally, this research examined only one compound (apigenin) in one disease model, so we don’t know how it might work in different populations or disease stages. Human clinical trials would be necessary to confirm these findings and determine safe and effective doses for people.
The Bottom Line
Based on this research, apigenin shows promise as a potential treatment for fatty liver disease, but it’s too early to recommend it as a therapy. The evidence is strong in animal models (high confidence in the animal study results) but weak for human application (no human studies yet). People with fatty liver disease should continue following established medical advice: maintaining a healthy weight, eating a balanced diet, limiting alcohol, and working with their healthcare provider. Those interested in apigenin should discuss it with their doctor before using supplements.
This research is most relevant to people with metabolic-associated fatty liver disease, researchers studying liver disease and gut health, and pharmaceutical companies developing new treatments. People with obesity, type 2 diabetes, or metabolic syndrome should be aware of this research since these conditions increase fatty liver disease risk. However, this research is preliminary and shouldn’t change current medical practice. Healthcare providers treating fatty liver disease should monitor this research as it progresses toward human studies.
In the mouse study, apigenin produced measurable improvements in liver health. However, translating these results to humans typically takes 5-10 years of additional research, including safety studies and clinical trials. If apigenin eventually becomes available as a treatment, benefits would likely develop over weeks to months of consistent use, similar to other metabolic interventions. People shouldn’t expect immediate results and should maintain realistic expectations about timelines.
Frequently Asked Questions
Can apigenin treat fatty liver disease in humans?
Apigenin shows promise in mouse studies for treating fatty liver disease, but human clinical trials haven’t been conducted yet. Current evidence is limited to animal research, so it cannot be recommended as a treatment until human studies confirm safety and effectiveness.
What foods contain apigenin naturally?
Apigenin is found in chamomile tea, parsley, celery, oregano, basil, and other herbs and vegetables. Consuming these foods may provide apigenin, though the amounts are typically much lower than doses used in research studies.
How does apigenin help the liver according to this research?
The study found apigenin works by changing gut bacteria composition, increasing beneficial Lactobacillus and decreasing harmful bacteria. This shift lowers homocysteine levels, reducing oxidative stress and inflammation that damage the liver, ultimately improving fat metabolism and liver function.
Should I take apigenin supplements if I have fatty liver disease?
You should discuss apigenin supplements with your doctor before using them. While this research is encouraging, it’s based on animal studies only. Proven treatments for fatty liver disease include weight loss, healthy diet, exercise, and limiting alcohol—focus on these first.
When might apigenin become available as a fatty liver disease treatment?
If apigenin progresses through human clinical trials successfully, it typically takes 5-10 years from animal studies to potential therapeutic availability. Currently, it remains a research compound, not an approved medical treatment for fatty liver disease.
Want to Apply This Research?
- Track liver health markers if available through your healthcare provider: measure ALT and AST enzymes (liver function indicators) every 3 months, and monitor weight, waist circumference, and dietary adherence weekly through the app
- Use the app to increase intake of apigenin-rich foods (chamomile tea, parsley, celery, oregano) while simultaneously tracking liver-supporting habits: alcohol avoidance, regular exercise (150 minutes weekly), and maintaining a healthy weight through balanced nutrition
- Create a 12-week monitoring protocol within the app: weekly logging of apigenin-rich food consumption, daily exercise and alcohol tracking, monthly weight checks, and quarterly liver function test results from your doctor to assess whether dietary changes correlate with improved liver health markers
This article discusses preliminary research conducted in animals and should not be interpreted as medical advice. Apigenin has not been approved by the FDA as a treatment for fatty liver disease. Anyone with fatty liver disease should work with their healthcare provider to develop an appropriate treatment plan based on established medical evidence. Do not start, stop, or change any medications or supplements without consulting your doctor. This research represents early-stage findings that require human clinical trials before clinical application.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.